Bioavailability of Vitamin D Encapsulated in Casein Micelles, Compared to Its Bioavailability in the Milk-fat, or in a Synthetic Emulsifier Currently Used for Supplementation and Enrichment
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The encapsulation within CM may improve bioavailability (BA) of vitamin D (VD), even in absence of fat.
As a model the investigators have chosen nonfat yoghurt. The investigators will prepare yoghurts from 4 milks: (1) Skimmilk enriched with 50,000 IU/150gr VD encapsulated in CM2 ; (2) 3% fat milk wherein same dose of VD - dissolved in milk fat and homogenized into skimmilk; (3) 3% fat milk wherein VD, at same dose, will be in CM; (4) Placebo: unenriched skimmilk. 120 healthy adults aged 18-65 will randomized to 5 groups and receive 150 gr yoghurt. Blood will be drawn before ingestion and on days 1,7,14. 25(OH)D will be det. by CMIA. In vitro simulated digestion will be studied.
Expected results: The BA of VD in CM would not be lower than in fat
| Condition | Intervention |
|---|---|
|
Healthy Individuals |
Dietary Supplement: Group 1 Dietary Supplement: Group 2 Dietary Supplement: group 3 Dietary Supplement: Group 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Bio-equivalence Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention |
- Bioavailability of vitamin D encapsulated in casein micelles, compared to its bioavailability in the milk-fat. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]As a model we have chosen nonfat yoghurt. We will prepare yoghurts from 4 milks: (1) Skimmilk enriched with 50,000 IU/150gr VD encapsulated in CM2 ; (2) 3% fat milk wherein same dose of VD - dissolved in milk fat and homogenized into skimmilk; (3) 3% fat milk wherein VD, at same dose, will be in CM; (4) Placebo: unenriched skimmilk. 120 healthy adults aged 18-65 will randomized to 5 groups and receive 150 gr yoghurt. Blood will be drawn before ingestion and on days 1,7,14. 25(OH)D will be det. by
| Estimated Enrollment: | 120 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Skimmilk enriched with VD encapsulated in CM |
Dietary Supplement: Group 1
Skimmilk enriched with VD encapsulated in CM
|
|
Active Comparator: VD will be dissolved in milkfat and homogenized into skimmilk
VD will be dissolved in milkfat and homogenized into skimmilk
|
Dietary Supplement: Group 2
VD will be dissolved in milkfat and homogenized into skimmilk
|
|
Active Comparator: 3% fat milk wherein the VD will be in CM
3% fat milk wherein the VD will be in CM
|
Dietary Supplement: group 3
3% fat milk wherein the VD will be in CM
|
|
Active Comparator: Placebo: un-enriched skimmilk.
Placebo: un-enriched skimmilk.
|
Dietary Supplement: Group 4
Placebo: un-enriched skimmilk.
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy volunteers
Exclusion Criteria:
- Metabolic disorder
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Sophia Ish-Shalom, Rambam Health Care Campus |
| ClinicalTrials.gov Identifier: | NCT01259570 History of Changes |
| Other Study ID Numbers: | 3000007066 |
| Study First Received: | December 12, 2010 |
| Last Updated: | December 13, 2010 |
| Health Authority: | Israel: Ministry of Health |
ClinicalTrials.gov processed this record on May 19, 2013